MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-373-1500
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees9
Next Earnings Date2/12/2020 (Estimated)
OptionableOptionable
MediciNova (NASDAQ:MNOV) Frequently Asked Questions
What is MediciNova's stock symbol?
MediciNova trades on the NASDAQ under the ticker symbol "MNOV."
How were MediciNova's earnings last quarter?
MediciNova, Inc. (NASDAQ:MNOV) released its quarterly earnings data on Thursday, October, 29th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.04. View MediciNova's Earnings History.
When is MediciNova's next earnings date?
What price target have analysts set for MNOV?
1 brokers have issued 12-month price objectives for MediciNova's shares. Their forecasts range from $22.00 to $22.00. On average, they anticipate MediciNova's stock price to reach $22.00 in the next year. This suggests a possible upside of 180.3% from the stock's current price. View Analyst Price Targets for MediciNova.
What is the consensus analysts' recommendation for MediciNova?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MediciNova.
Has MediciNova been receiving favorable news coverage?
News stories about MNOV stock have trended extremely negative on Sunday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MediciNova earned a news impact score of -5.0 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for MediciNova.
Who are some of MediciNova's key competitors?
Some companies that are related to MediciNova include Constellation Pharmaceuticals (CNST), Innoviva (INVA), Enanta Pharmaceuticals (ENTA), BELLUS Health (BLUSF), Supernus Pharmaceuticals (SUPN), Y-mAbs Therapeutics (YMAB), Radius Health (RDUS), Esperion Therapeutics (ESPR), Odonate Therapeutics (ODT), Arvinas (ARVN), ZEALAND PHARMA/S (ZEAL), Theravance Biopharma (TBPH), Principia Biopharma (PRNB), Karyopharm Therapeutics (KPTI) and Wave Life Sciences (WVE).
What other stocks do shareholders of MediciNova own?
Who are MediciNova's key executives?
MediciNova's management team includes the folowing people:
- Dr. Yuichi Iwaki, Co-Founder, Pres, CEO & Exec. Director (Age 69)
- Mr. Masatsune Okajima, Head of Japanese Office & VP (Age 51)
- Dr. Kazuko Matsuda M.P.H., M.D., Ph.D., MPH, Chief Medical Officer (Age 53)
- Ms. Carla Reyes, Chief Financial Officer (Age 47)
- Mr. John O'Neil CPA, Controller
Who are MediciNova's major shareholders?
MediciNova's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Alps Advisors Inc. (0.20%), California Public Employees Retirement System (0.13%) and Tower Research Capital LLC TRC (0.01%). View Institutional Ownership Trends for MediciNova.
Which major investors are selling MediciNova stock?
Which major investors are buying MediciNova stock?
How do I buy shares of MediciNova?
Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is MediciNova's stock price today?
One share of MNOV stock can currently be purchased for approximately $7.85.
How big of a company is MediciNova?
MediciNova has a market capitalization of $344.14 million. The biopharmaceutical company earns $-14,670,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. MediciNova employs 9 workers across the globe.View Additional Information About MediciNova.
What is MediciNova's official website?
How can I contact MediciNova?
MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected]
MarketBeat Community Rating for MediciNova (NASDAQ MNOV)
MarketBeat's community ratings are surveys of what our community members think about MediciNova and other stocks. Vote "Outperform" if you believe MNOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNOV will underperform the S&P 500 over the long term. You may vote once every thirty days.
